Moderna Inc. (MRNA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Moderna Inc. (MRNA) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How MRNA Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $1.94B | 55.3% | -158.1% | -$2.82B | -$2.06B | -36.5% |
| FY 2024 | $3.24B | 54.8% | -121.9% | -$3.56B | -$4.05B | -34.7% |
| FY 2023 | $6.85B | 44% | -61.9% | -$4.71B | -$3.43B | -11.3% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring MRNA)
- ✓Live walkthrough of MRNA's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
MRNA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -39.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MRNA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MRNA. Explore sector supply chains on /butterfly.
MRNA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Moderna Inc. (MRNA)?
In FY 2025 (10-K), MRNA converted $1.9B of revenue into a 55.3% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).